81 related articles for article (PubMed ID: 1685075)
1. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of plasma prolactin in breast cancer: comparison with the expression of c erb B-2 oncoprotein.
Bhatavdekar JM; Patel DD; Sherbet GV; Giri DD; Karelia NH; Vora HH; Shah NG; Suthar TP; Nadkarni SP; Balar DB
Eur J Surg Oncol; 1993 Oct; 19(5):409-13. PubMed ID: 8104829
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer.
Schimmelpenning H; Eriksson ET; Falkmer UG; Rutqvist LE; Johansson H; Fallenius A; Auer GU
Eur J Surg Oncol; 1992 Dec; 18(6):530-7. PubMed ID: 1362164
[TBL] [Abstract][Full Text] [Related]
5. TAG 12 expression as a prognostic factor in female breast cancer.
Eskelinen M; Lipponen P; Syrjänen K
Anticancer Res; 1991; 11(5):1683-6. PubMed ID: 1768037
[TBL] [Abstract][Full Text] [Related]
6. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
[TBL] [Abstract][Full Text] [Related]
8. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
[TBL] [Abstract][Full Text] [Related]
10. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Eskelinen M; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
Heintz NH; Leslie KO; Rogers LA; Howard PL
Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright C; Angus B; Nicholson S; Sainsbury JR; Cairns J; Gullick WJ; Kelly P; Harris AL; Horne CH
Cancer Res; 1989 Apr; 49(8):2087-90. PubMed ID: 2564806
[TBL] [Abstract][Full Text] [Related]
14. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen].
Antunes A; Silva T; Godinho I; Amaral N; Oliveira C
Acta Med Port; 2004; 17(4):271-6. PubMed ID: 15941551
[TBL] [Abstract][Full Text] [Related]
16. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
Lipponen PK
J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
[TBL] [Abstract][Full Text] [Related]
19. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
20. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
